Abstract
Arachidonic acid (AA) inhibits the binding of [3H]quinclidinyl benzilate ([3H]QNB) to the human brain muscarinic cholinergic receptor (mAChR). AA inhibits at lower concentrations in the absence of glutathione (I50=15 µM) than in the presence of glutathione (I50=42 µM). Inhibition of mAChR binding shows specificity for AA and is reduced with loss of one or more double bonds or with either a decrease or increase in the length of the fatty acid chain. Metabolism of AA by the lipoxygenase, epoxygenase, or fatty acid cyclooxygenase pathways is not required for the inhibitory activity of AA on mAChR binding. Inhibition of [3H]QNB binding by AA is reversible. While decreasing Bmax, AA increased the apparent KD for [3H]QNB and for the more polar antagonist [3H]NMS. In addition, AA inhibits binding of the agonist [3H]oxotremorine-M (I50=60 µM) and is the first mediator of mAChR action to be shown to reversibly inhibit mAChR binding. The feedback inhibition of the mAChR by AA may serve a homeostatic function similar to the reuptake and hydrolysis of acetylcholine following cholinergic nerve transmission.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aronstam R. S., Abood L. G., and Baumgold J. (1977) Role of phospholipids in muscarinic binding by neural membranes.Biochem. Pharmacol. 26, 1689–1695.
Axelrod J., Burch R. M., and Jelsema C. L. (1988) Receptor-mediated activation of phospholipase A2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers.Trends Neurosci. 11, 117–123.
Conklin B. R., Brann M. R., Buckley N. J., Ma A. L., Bonner T. I., and Axelrod J. (1988) Stimulation of arachidonic acid release and inhibition of mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells.Proc. Natl. Acad. Sci. USA 85, 8698–8702.
Davies P. (1985) A critical review of the role of the cholinergic systems in human memory and cognition.Ann. NY Acad. Sci. 444, 212–216.
Davies P. and Maloney A. J. F. (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease.Lancet 2, 1403.
De Souza E. B. (1993) Preclinical strategies for symptomatic treatment of cognitive deficits seen in Alzheimer’s disease: focus on cholinergic mechanisms, inAlzheimer’s Disease: Advances in Clinical and Basic Research (Corain B., Iqbal K., Nicolini M., Winblad B., Wisniewski H., and Zatta P., eds.), Wiley, Chichester, UK, pp. 539–548.
Drachman D. A. and Leavitt J. (1974) Human memory and the cholinergic system: a relationship to aging?Arch. Neurol. 30, 113–121.
Felder C. C., Dieter P., Kinsella J., Tamura K., Kanterman R. Y., and Axelrod J. (1990) A transfected m5 muscarinic acetylcholine receptor stimulates phospholipase A2 by inducing both calcium influx and activation of protein kinase C.J. Pharmacol. Exp. Ther. 256, 1140–1147.
Fields J. Z., Roeske W. R., Morkin E., and Yamamura M. I. (1978) Cardiac muscarinic cholinergic receptors.J. Biol. Chem. 253, 3251–3258.
Frey W. H. II, Emory C. R., Wiebenga M. E., Saxena S., Cardelli D., Ala T.-A., and Tollfeson G. D. (1994) Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer’s brain.Brain Res. 655, 153–160.
Frey W. H. II, Najarian M. M., Kumar K. S., Emory C. R., Menning J. C., Johnson M. N., and Ala T. A. (1996) Endogenous Alzheimer’s brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor.Brain Res. 714, 87–94.
Frey W. H. II, Kjome J., Swenson K., Fraticelli A. I., Johnson M. N., Venters H. D. Jr., and Ala T. A. (1997) Inhibition of antagonist binding to the muscarinic receptor by arachidonic acid (abstract).FASEB J. 11(9), A919.
Glass D. B., Frey W. H. II, Carr D. W., and Goldberg N. D. (1977) Stimulation of human platelet guanylate cyclase by fatty acids.J. Biol. Chem. 252, 1279–1285.
Kanfer J. N., Singh I. N., Pettegrew J. W., McCartney D. G., and Sorrentino G. (1996) Phospholipid metabolism in Alzheimer’s disease and in a human cholinergic cell.J. Lipid Mediators Cell Signall. 14, 361–363.
Katzman R. and Thal L. J. (1989) The neurochemistry of Alzheimer’s disease, inBasic Neurochemistry (Siegel G., Arganoff B., Alberts R. W., and Molinoff P., eds.), Raven, New York, pp. 827–838.
Kinouchi H., Imaizumi S., Yoshimoto T., and Motomiya M. (1990) Phenytoin affects metabolism of free fatty acids and nucleotides in rat cerebral ischemia.Stroke 21, 1326–1332.
Marks M. J. and Collins A. C. (1982) Characterization of nicotine binding in mouse brain and comparison with the binding of α-bungarotoxin and quinuclidinly benzilate.Mol. Pharmacol. 22, 554–564.
Maruyama Y. (1990) Inhibitory effects of arachidonic acid on muscarinic current response in single pancreatic acinar cells of rats.J. Physiol. 430, 471–482.
Rauch B., Colvin R. A., and Messineo F. C. (1989) Inhibition of [3H]-quinuclidinyl benzylate binding to cardiac muscarinic receptor by long chain fatty acids can be attenuated by ligand occupation of the receptor.J. Mol. Cell Cardiol. 21, 495–506.
Staub F., Winkler A., Peters J., Kempski O., Kachel V., and Baetmann A. (1994) Swelling, acidosis, and irreversible damage of glial cells from exposure to arachidonic acid in vitro.J. Cerebral Blood Flow Metab. 14, 1030–1039.
Stephenson D. T., Lemere C. A., Selkoe D. J., and Clemens J. A. (1996) Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain.Neurobiol. Dis. 3(1), 51–63.
Strosznajder J., Samochocki M., and Duran M. (1994) Aging diminishes serotonin-stimulated arachidonic acid uptake and cholinergic receptor-activated arachidonic acid release in rat brain cortex membrane.J. Neurochem. 62, 1048–1054.
Tence M., Jocelyne C., Premont J., and Glowinski J. (1994) Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture.J. Pharmacol. Exp. Ther. 269, 646–653.
Tomlinson G. (1988) Inhibition of radioligand binding to receptors: a competitive business.TIPS 9, 159–162.
Venters H. D. Jr., Bonilla L. E., Jensen T., Garner H., Bordayo E., Najarian M. M., Ala T. A., Mason R. P., and Frey W. H. II. (1997) Heme from Alzheimer’s brain inhibits muscarinic receptor binding via thiyl radical generation.Brain Res. 764, 93–100.
Vijayaraghavan S., Huang B., Blumenthal E. M., and Berg D. K. (1995) Arachidonic acid as a possible negative feedback inhibitor of nicotinic acetylcholine receptors on neurons.J. Neurosci. 15, 3679–3687.
Whitehouse P. J., Price D. L., Struble R. G., Clark A. W., Coyle J. T., and DeLong M. R. (1982) Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain.Science 215, 1237–1239.
Wolfe L. S. (1989) Eicosanoids, inBasic Neurochemistry (Siegel G., Arganoff B., Alberts R. W., and Molinoff P., eds.), Raven, New York, pp. 399–414.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kjome, J.R., Swenson, K.A., Johnson, M.N. et al. Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid. J Mol Neurosci 10, 209–217 (1998). https://doi.org/10.1007/BF02761775
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02761775